alt news

29th September 2021

Diaprost Licenses its novel Theranostic Antibody, hu5A10, to Radiopharm Theranostics for Development in the Treatment and Diagnosis of Prostate Cancer.

The terms of an exclusive License Agreement, inclusive of an upfront payment and potential development and regulatory milestone payments over the life of the agreement, may exceed US$125 million. Diaprost announced today that it has agreed terms for an exclusive Licensing Agreement with Radiopharm Theranostics (RAD); an Australian based biotech startup, focused on building an […]

22nd February 2021

Diaprost Announces Promising New Study for Patients with Metastatic PCa

Diaprost announced today a publication in the journal of Clinical Cancer Research on PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates. The extensive preclinical study was conducted at Memorial Sloan Kettering Cancer Center (MSK) on Diaprost’s propriety antibody (hu5A10) targeting PSA. This rigorous preclinical evaluation of radiolabeled hu5A10-based […]

13th December 2016

Study demonstrates the feasibility of targeting human kallikrein-related peptidase 2 (hK2) for detection and monitoring of prostate cancer

A new publication in Science Translational Medicine demonstrates that in vivo targeting of the enzyme human kallikrein-related peptidase 2 (hK2) is a powerful tool that can be used for detection of prostate cancer and monitoring treatment by quantifying the activity of the androgen receptor pathway. Pressmeddelande Diaprost 13 dec 2016 Press release Diaprost dec 13 […]